🧬 Endocrinology Update: Mifepristone Lowers A1c, Gene Therapy for Diabetes, 3D-Printed Islets and More
From gene therapy and 3D-printed islets to affordable diabetes medications and post-fracture care innovations, this week’s roundup delivers the most critical updates in endocrinology—shaping the future of metabolic and hormonal health.
📌 In This Episode:
✔️ Mifepristone reduces HbA1c by 1.45 percent in tough-to-treat diabetes cases.
✔️ Gene therapy GPX-002 turns alpha cells into insulin-secreting beta-like cells in primate studies.
✔️ Anti-ACTH antibody Lu AG13909 earns orphan drug status for congenital adrenal hyperplasia.
✔️ Post-hip fracture osteoporosis care jumps from 10 to over 40 percent with pilot program support.
✔️ Youth delegates and celebrities push T1D research funding at Capitol Hill’s Children’s Congress.
✔️ BRENZAVVY becomes affordable at 1,400+ Publix stores, expanding T2D medication access.
✔️ Ireland opens first early-onset T2D clinic for patients under 40 in Sligo’s Benbulbin hub.
✔️ Romosozumab shows 72 percent fracture risk reduction and superior BMD in meta-analysis.
✔️ Lilli Health launches a PCOS app focused on insulin resistance with at-home testing.
✔️ Scientists 3D-print insulin-producing human islets that stay functional for over three weeks.
✔️ Biocon delivers over 100 million insulin cartridges to 345,000+ patients across Malaysia.
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on diabetes, thyroid disorders, and bone health.
#Endocrinology #diabetesresearch #T1D #T2D #PCOSAwareness #GeneTherapy #3DPrintingMedicine #OsteoporosisCare #HealthcareInnovation #Mifepristone #BRENZAVVY #Romosozumab #LilliHealth #Biocon #HormoneHealth #ClinicalTrials #LucidQuest #InsulinAccess #OrphanDrugs #MedicalBreakthroughs